Overall, our data supports GS as a first-tier test for nonsyndromic hearing loss as it led to additional diagnoses missed by ES, including the identification of a 125 kb deletion upstream of GJB2, which further refines the region critical for GJB2 expression and function. Here, GJB2 is linked to hearing loss disorder.